568 related articles for article (PubMed ID: 16053953)
1. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
O'Keefe JH; Abuissa H; Pitt B
Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
4. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
[TBL] [Abstract][Full Text] [Related]
5. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction Pitt B; Gheorghiade M; Zannad F; Anderson JL; van Veldhuisen DJ; Parkhomenko A; Corbalan R; Klug EQ; Mukherjee R; Solomon H;
Eur J Heart Fail; 2006 May; 8(3):295-301. PubMed ID: 16504579
[TBL] [Abstract][Full Text] [Related]
7. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
8. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
[TBL] [Abstract][Full Text] [Related]
11. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
[TBL] [Abstract][Full Text] [Related]
12. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Montalescot G; Pitt B; Lopez de Sa E; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Vincent J; Zannad F; ;
Eur Heart J; 2014 Sep; 35(34):2295-302. PubMed ID: 24780614
[TBL] [Abstract][Full Text] [Related]
13. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy.
Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P
Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172
[TBL] [Abstract][Full Text] [Related]
14. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
[TBL] [Abstract][Full Text] [Related]
15. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
16. Adherence to aldosterone-blocking agents in patients with heart failure.
Margolis J; Gerber RA; Roberts C; Gheorghiade M
Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Szucs TD; Holm MV; Schwenkglenks M; Zhang Z; Weintraub WS; Burnier M; Erne P
Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667
[TBL] [Abstract][Full Text] [Related]
18. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
[TBL] [Abstract][Full Text] [Related]
19. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
Pitt B; Ahmed A; Love TE; Krum H; Nicolau J; Cardoso JS; Parkhomenko A; Aschermann M; Corbalán R; Solomon H; Shi H; Zannad F
Hypertension; 2008 Aug; 52(2):271-8. PubMed ID: 18559720
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
Weir RA; Mark PB; Petrie CJ; Clements S; Steedman T; Ford I; Ng LL; Squire IB; Wagner GS; McMurray JJ; Dargie HJ
Am Heart J; 2009 Jun; 157(6):1088-96. PubMed ID: 19464421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
